MAZE Form 4: SVP Finance receives 22,000 restricted stock units

Rhea-AI Filing Summary

Amy Bachrodt, SVP Finance of Maze Therapeutics (MAZE), was granted 22,000 restricted stock units on 09/22/2025. Each unit converts to one share of common stock upon settlement and the reporting person beneficially owns 22,000 shares after the reported transaction.

The award vests in two equal installments: 11,000 RSUs on September 1, 2026 and 11,000 RSUs on September 1, 2027, contingent on continued service. The RSUs have no expiration; they either vest or are cancelled before vesting. The Form 4 was executed by an attorney-in-fact on 09/24/2025.

Positive

• 22,000 restricted stock units were granted to Amy Bachrodt, increasing her direct beneficial ownership to 22,000 shares as reported
• Clear vesting schedule: 11,000 RSUs vest on 09/01/2026 and 11,000 RSUs vest on 09/01/2027, showing time-based retention alignment

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: A routine executive equity grant that ties senior finance leadership compensation to company equity over two years.

This Form 4 documents a standard time-based restricted stock unit grant to the companys SVP of Finance. The two-step vesting schedule over 12 and 24 months aligns the executives interests with shareholder outcomes without indicating accelerated vesting or performance-based conditions. From a governance perspective, this is a common retention and alignment tool and does not, by itself, signal governance concerns or material change in control or compensation policy.

Compensation Analyst

TL;DR: 22,000 RSUs granted, vesting 50% in 2026 and 50% in 2027; typical time-based award for retention.

The filing shows 22,000 restricted stock units awarded with explicit vesting dates and no expiration clause, meaning the award is strictly time-contingent on continued service. The size of the award relative to outstanding shares is not disclosed here, so assessment of dilution or materiality cannot be made from this form alone. No cash price was paid and ownership is recorded as direct following the award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bachrodt Amy

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/22/2025		A		22,000		(2)	(3)	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

2. The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.

3. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Amy Bachrodt (MAZE) acquire on 09/22/2025?

She was granted 22,000 restricted stock units (RSUs), each convertible into one share of common stock upon settlement.

When do the RSUs granted to Amy Bachrodt vest?

The award vests in two equal installments: 11,000 RSUs on 09/01/2026 and 11,000 RSUs on 09/01/2027, subject to continued service.

How many shares does Amy Bachrodt beneficially own after the reported transaction?

The Form 4 reports 22,000 shares beneficially owned following the transaction.

Do the restricted stock units granted to Amy Bachrodt expire?

No. The filing states the RSUs do not expire; they either vest or are cancelled prior to the vesting date.

Who signed the Form 4 and when was it dated?

The Form 4 was executed by Courtney Phillips, as attorney-in-fact and dated 09/24/2025.